Evidence map›Paper›PMID 36830829›Full record

ArticleBiomedicines2023

Fluorescence Angiography with Dual Fluorescence for the Early Detection and Longitudinal Quantitation of Vascular Leakage in Retinopathy.

Benjamin Pomeroy, Alexander W Venanzi, Wei Li, Abigail S Hackam, Midhat H Abdulreda

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Effect of ranibizumab on diabetic retinopathyWorld journal of diabetes · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Benjamin PomeroyDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Alexander W VenanziDepartment of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Wei LiDepartment of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.ORCID 0000-0001-9566-8764
Abigail S HackamDepartment of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Midhat H AbdulredaDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.ORCID 0000-0002-0146-5876
University of Miami · US

Funding

Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Marco Ruggeri · 2004 to 2026
$12.2M
A selective angiogenesis blocker to treat retinopathy of prematurityR24EY028764 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LI, WEI · 2019 to 2023
$7.6M
A Diabetic Retinopathy-Associated Vascular Permeability FactorR01EY027749 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LI, WEI · 2018 to 2022
$2.2M
Role of macrophages in pancreatic islet graft rejectionK01DK097194 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ABDULREDA, MIDHAT H · 2013 to 2015
$415k
Mechanisms of islet transplant immune toleranceR56AI130330 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ABDULREDA, MIDHAT H · 2017 to 2017
$384k
National Institute of Allergy and Infectious Diseases R56AI130330NEI NIH HHS P30 EY014801NEI NIH HHS P30EY014801NEI NIH HHS R01 EY027749NEI NIH HHS R24 EY028764NIAID NIH HHS R56 AI130330NIDDK NIH HHS K01 DK097194NIDDK NIH HHS K01DK097194
6 · The paper itself

Abstract

backgroundDiabetic retinopathy (DR) afflicts more than 93 million people worldwide and is a leading cause of vision loss in working adults. While DR therapies are available, early DR development may go undetected without treatment due to the lack of sufficiently sensitive tools. Therefore, early detection is critically important to enable efficient treatment before progression to vision-threatening complications. A major clinical manifestation of early DR is retinal vascular leakage that may progress from diffuse to more localized focal leakage, leading to increased retinal thickness and diabetic macular edema (DME). In preclinical research, a hallmark of DR in mouse models is diffuse retinal leakage without increased thickness or DME, which limits the utility of optical coherence tomography and fluorescein angiography (FA) for early detection. The Evans blue assay detects diffuse leakage but requires euthanasia, which precludes longitudinal studies in the same animals.

methodsWe developed a new modality of ratiometric fluorescence angiography with dual fluorescence (FA-DF) to reliably detect and longitudinally quantify diffuse retinal vascular leakage in mouse models of induced and spontaneous DR.

resultsThese studies demonstrated the feasibility and sensitivity of FA-DF in detecting and quantifying retinal vascular leakage in the same mice over time during DR progression in association with chronic hyperglycemia and age.

conclusionsThese proof-of-concept studies demonstrated the promise of FA-DF as a minimally invasive method to quantify DR leakage in preclinical mouse models longitudinally.

Indexed as

diabetic macular edema (DME)diabetic retinopathy (DR)dual fluorescencefluorescein angiography (FA)intravital imaginglongitudinal quantitationnoninvasive in vivo imagingproliferative diabetic retinopathy (PDR)retinal vascular leakage

Identifiers

PMID36830829
PMCPMC9953145
OpenAlexW4317931905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.